ArticleBMC cancer2026
GPC2 provides prognostic value in pan-pediatric cancers and is associated with MYCN amplification in neuroblastoma: bioinformatics analysis and validation.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundGlypican-2 (GPC2), a member of the GPC gene family, primarily functions in developing neural and thyroid cancer tissues, exerting influence on protein transduction, cellular proliferation and differentiation, as well as oncogenic signatures. GPC2 exhibits significant overexpression in the majority of neuroblastoma (NB) samples while remaining nearly undetectable in normal pediatric tissue samples.
methodsOverall survival (OS) was employed as a key parameter to investigate the correlation between GPC2 expression and pan-pediatric cancers. To assess the association between GPC2 expression and clinical parameters of NB, box plots followed by t-tests were utilized. Protein-protein interaction (PPI) networks and gene-gene interaction networks were constructed. Functional roles were determined through Ontology (GO) term enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. The XCell was employed to analyze the relationship between GPC2 expression and immune-related cells. Additionally, we retrospectively collected clinical data and survival information from a cohort of 51 patients diagnosed with NB and conducted immunohistochemistry (IHC) on the specimens as a validation set.
resultsA significant correlation between elevated GPC2 expression and reduced survival rates was observed in NB and brain tumors (P < 0.05). Notably, high GPC2 expression showed a non-significant trend toward reduced survival in four other pediatric tumor types except osteosarcoma. Notably, the MYCN amplified group exhibited significantly higher levels of GPC2 expression. Furthermore, GPC2 expression showed a positive correlation with infiltrating basophils, CD4 T cells, CD8 T cells, CD8 naïve T cells, Tgd cells, Th1 cells, Th2 cells and pro B cells, while demonstrating a negative correlation with infiltrating fibroblasts, macrophages M1 and M2 subtypes, monocytes neutrophils and pDCs. Among all 51 pediatric NB patients analyzed in this study, the MYCN amplified group displayed significantly higher levels of GPC2 expression compared to the MYCN not-amplified group. Additionally, survival analysis revealed that individuals with high GPC2 expression had significantly worse OS compared to those with low expression (P = 0.018).
conclusionElevated GPC2 expression was significantly correlated with reduced survival rates in NB and brain tumors (P < 0.05), with a non-significant trend toward reduced OS in four other pediatric tumor types. Furthermore, the expression level of GPC2 in NB showed a positive association with MYCN status and levels of immune cell infiltration
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.